Olivier Lantrès | Fieldfisher
Skip to main content
Professional background

Professional background

Olivier is an expert on regulatory issues in the life sciences and healthcare sectors, in particular concerning medical devices, pharmaceutical and phytopharmaceutical products and cosmetics.

His main area of practice involves matters relating to advertising of pharmaceutical products, relationships with healthcare practitioners, clinical trials, and advising clients in the context of monitoring by the health authorities.

He is a Doctor of Law (magna cum laude) and ranked as a 'Leading Individual' by Legal 500 (2022) as well as Band 1 in Chambers 2022. In addition to this, He is also recognised and ranked by a number of other directories including PLC Which Lawyer, Best Lawyers in France and Décideurs Stratégie Finance Droit.

He was awarded a first prize by the French Healthcare Law Association for his work and also is a member of the professional associations ACIP and AMIPS.

He joined Fieldfisher as a Partner in 2008 after having worked with Price Waterhouse Coopers and Proskauer Rose LLP.

In addition to his native French, he is fluent in English.

 

Awards & recognition

Awards & recognition

Client
We had the pleasure of working with Mila Kovalenko, who exhibits outstanding professionalism and thorough knowledge of her areas of practice.
Chambers & Partners 2022
He has extremely good knowledge of the healthcare sector. He is always available and is very efficient.
The Legal 500 EMEA 2022
Olivier Lantrès has solid experience and excellent knowledge of the health sector and the issues encountered by his clients. He is surrounded by a competent and very responsive team.

He is always there and always finds relevant and business-oriented solutions for his clients. Olivier has an activity established at Fieldfisher for many years which allows him to work transversally with the other teams of the firm.

He is very responsive and, with his team, produces quality work at ‘fair’ prices.
Chambers & Partners 2026

Leading individual : Band 1 

Individual Editorial
Olivier Lantrès maintains a leading regulatory practice, advising prominent pharmaceutical and medical device companies.

Strengths
"He is excellent."

Authored pieces

All Resources
A gloved scientist uses a pipette to add liquid to a 96-well plate in a laboratory. Scientific equipment and a computer screen displaying chemical formulas are visible in the background, highlighting a research environment.
Life Sciences
Insight

The EU Biotech Act: From Regulatory Reform to Business Action

24.06.2026
Learn more
Close-up of a laboratory setting featuring a plastic test tube rack and graduated pipettes submerged in water with bubbles surrounding them. The background transitions from pink to blue tones, creating a visually appealing scientific scene.
Life Sciences
Insight

The European Court of Justice opens the way for chemically synthesised generics of reference biological medicinal products

29.04.2026
Learn more
A digital illustration of a glowing DNA double helix strand made up of colorful light particles, set against a dark background with purple and blue hues.
Life Sciences
Insight

ECJ's landmark ruling on defective products liability: What it means for life sciences manufacturers

30.03.2026
Learn more
Close-up of several blister packs filled with blue and white capsules. The capsules are arranged in a grid-like pattern, and the lighting highlights some of the rows, giving a metallic sheen to the packaging.
Life Sciences
Insight

The European Court of Justice issues a landmark decision concerning defective medicines, facilitating patient indemnification

27.03.2026
Learn more
Life Sciences
Insight

LFSS 2026: What the new Supplementary Contribution means for Pharma

10.03.2026
France’s Social Security Financing Act for 2026 (LFSS 2026) introduces a change that reshapes how pharmaceutical companies manage their financial exposure. At the centre of the reform is a new 'Supplementary Contribution' on turnover (alongside the basic and additional turnover contributions), which is a measure designed to bring more clarity to a system that, for years, has been criticised as unpredictable and increasingly unmanageable.
Learn more

What others say…

Client
We had the pleasure of working with Mila Kovalenko, who exhibits outstanding professionalism and thorough knowledge of her areas of practice.
Chambers & Partners 2022
He has extremely good knowledge of the healthcare sector. He is always available and is very efficient.
The Legal 500 EMEA 2022
Olivier Lantrès has solid experience and excellent knowledge of the health sector and the issues encountered by his clients. He is surrounded by a competent and very responsive team.

He is always there and always finds relevant and business-oriented solutions for his clients. Olivier has an activity established at Fieldfisher for many years which allows him to work transversally with the other teams of the firm.

He is very responsive and, with his team, produces quality work at ‘fair’ prices.